CPM has patented a culture medium for Mycoplasma
Developed to isolate non-cultivable species from clinical samples, improving microbiological diagnostics. Reflects CPM's applied research approach.
See the latest news and media coverage for CPM SRL. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biomedical technologies provider for hospital projects
cpmsrl.euLast updated
In short: CPM SRL introduced its UROGEN transport medium, attended major 2026 industry congresses, and expanded its global distributor network.
Developed to isolate non-cultivable species from clinical samples, improving microbiological diagnostics. Reflects CPM's applied research approach.
Since 1986 it works with laboratories, hospitals and international partners in different contexts, thanking teams and collaborators. It continues to develop reliable solutions.
CPM provides clinical data, IVDR support, onboarding, and after-sales services. They seek partners with hospital access, local teams, and tender experience. Apply via Fabio Ronci or book a call.
The patent covers isolation of clinical Mycoplasma samples, including non-culturable species in traditional media. This media is used in their unique products.
NEW YORK, March 3, 2026 /PRNewswire/ -- American Securities LLC ("American Securities"), a leading U.S. private equity firm, today announced that it has entered into...
CPM Gold Trade Recommendation. Time Stamp. Prices as of 9:20 a.m. EST 22 December 2025 $4,460 (Basis the February 2026 Comex contract).
KOCHI: It began as a bold political move, but ended up a costly mistake. In trying to redraw its voter map, the CPM appears to...
The Perugia Court of Appeal has acquitted Luca Tramannoni, CEO of Cpm Gestioni termiche, a Recanati company in the Sambucheto industrial area (where it is headquartered...
Track CPM SRL and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to CPM SRL and other trending companies.